In 2026, U.S. agreements lower costs of GLP-1 drugs for obesity and diabetes, impacting Medicare and Medicaid coverage with a focus on starter dose affordability and access limitations.

CMS's current inclusion of noncovered self-administered drug prices in Medicare Part B payment calculations inflates costs for Stelara biosimilars. OIG recommends revising pricing methodology to achieve savings.

Federal rescheduling of cannabis to Schedule III and a Medicare pilot program are set to advance U.S. healthcare integration, research, and institutional investment in cannabis-derived products.

Explore common financial shocks retirees face, including Medicare gaps and housing expenses, with expert insights on building adaptable retirement plans and liquidity reserves.

The AMA's 2024 report reveals significant concentration in U.S. commercial and Medicare Advantage health insurance markets, raising concerns over competition and consumer choice.

A contract dispute between Optum and Humana in Washington state spotlights risks of vertical integration in Medicare Advantage, impacting senior beneficiaries and market competition.

Explore critical U.S. healthcare challenges including hospital staffing issues, prisoner healthcare vacancies, advances in robotic surgery, and insurance industry shifts in value-based care and provider network disputes.

Discover Reuters' role as a premier global provider of financial and business news, data, and risk screening tools, delivering trusted insights under Thomson Reuters Trust Principles.

A Medicare fraud scheme in Oconee County, SC, targets seniors and veterans with bogus medical equipment bills, highlighting ongoing challenges in Medicare compliance and fraud prevention.

HHS renews LymeX Innovation Accelerator to boost AI-driven diagnostics and expands Medicare support for Lyme disease patients, advancing national care strategies.